Harnessing the immunostimulatory properties of oncolytic reovirus for anticancer immunotherapy

Groeneveldt, P.C.

Citation
Groeneveldt, P. C. (2023, November 23). *Harnessing the immunostimulatory properties of oncolytic reovirus for anticancer immunotherapy*. Retrieved from https://hdl.handle.net/1887/3663612

Version:	Publisher's Version
License:	Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from:	https://hdl.handle.net/1887/3663612

Note: To cite this publication please use the final published version (if applicable).

Harnessing the immunostimulatory properties of oncolytic reovirus for anticancer immunotherapy

Christianne Groeneveldt

© 2023 Christianne Groeneveldt

ISBN: 978-94-6483-394-2
Printing: Ridderprint, ridderprint.nl
Cover: Evelien Jagtman, evelienjagtman.com
Layout and design: Tara Schollema, persoonlijkproefschrift.nl

The research described in this thesis was performed at the Department of Medical Oncology of the Leiden University Medical Center, Leiden and was financially supported by a PhD fellowship from Leiden University Medical Center, the Dutch Cancer Society Bas Mulder Award (11056) and the Support Casper campaign by the Dutch foundation 'Stichting Overleven met Alvleesklierkanker' (project numbers SOAK 17.04, 19.03 and 22.02).

Printing of this thesis was financially supported by the Department of Medical Oncology and the Stichting Overleven met Alvleesklierkanker.

All rights reserved. No part of this thesis may be reproduced, stored, or transmitted in any way or by any means without permission of the author.

Harnessing the immunostimulatory properties of oncolytic reovirus for anticancer immunotherapy

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op donderdag 23 november 2023
klokke 10.00 uur

door

Pietje Centina Groeneveldt
geboren te Dordrecht
in 1995

PROMOTORES
Prof. dr. S.H. van der Burg
Prof. dr. T. van Hall

CO-PROMOTOR
Dr. A.G. van Montfoort

LEDEN PROMOTIECOMMISSIE

Prof. dr. E.J.H.J Wiertz	UMC Utrecht
Prof. dr. T.D. de Gruijl	Amsterdam UMC
Prof. dr. M.H.M. Heemskerk	
Prof. dr. R.E.M Toes	
Prof. dr. M. Yazdanbakhsh	

TABLE OF CONTENTS

Chapter 1	General Introduction	7
PART A	**EXPLOITATION OF THE REOVIRUS-SPECIFIC T-CELL RESPONSE FOR ANTICANCER THERAPY**	
Chapter 2	Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy *Journal for ImmunoTherapy of Cancer 2020;8:e001191*	25
Chapter 3	Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy *Journal for ImmunoTherapy of Cancer 2022;10:e004464*	69
PART B	**THE EFFECT OF PREEXISTING IMMUNITY ON REOVIRUS THERAPY**	
Chapter 4	Preexisting immunity: barrier or bridge to effective oncolytic virus therapy? *Cytokine & Growth Factor Reviews 2023;70:1-12*	115
Chapter 5	Neutralizing antibodies impair the efficacy of reovirus as oncolytic agent but permit effective combination with T-cell-based immunotherapy *Manuscript submitted*	147
Addendum I	$CD4^+$ T-cell depletion abrogates NAb production and improves the efficacy of reovirus monotherapy	185
PART C	**BLOCKADE OF TGF-β SIGNALING TO IMPROVE REOVIRUS-BASED IMMUNOTHERAPY**	
Chapter 6	Immunotherapeutic potential of TGF-β inhibition and oncolytic viruses *Trends in Immunology 2020;41(5):406-420*	195
Chapter 7	Intratumoral differences dictate the outcome of TGF-β blockade on the efficacy of viro-immunotherapy *Cancer Research Communications 2023;3(2):325–337*	223
Addendum II	TGF-β blockade improves Reo&αPD-L1 therapy in the murine colon MC38 tumor model	259
Chapter 8	Summarizing Discussion and Future Perspectives	265
Appendices	Nederlandse samenvatting voor niet-ingewijden	288
	List of publications	295
	About the author	298
	About the cover	299
	Dankwoord	300